Scandion Oncology AS (OSTO:SCOL) ROE % Adjusted to Book Value : -277.83% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS ROE % Adjusted to Book Value?

Scandion Oncology AS's ROE % for the quarter that ended in Dec. 2024 was -383.41%. Scandion Oncology AS's PB Ratio for the quarter that ended in Dec. 2024 was 1.38. Scandion Oncology AS's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -277.83%.

Scandion Oncology AS ROE % Adjusted to Book Value Historical Data

The historical data trend for Scandion Oncology AS's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS ROE % Adjusted to Book Value Chart

Scandion Oncology AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.56

-14.47

-82.99

-22.45

-137.81

Scandion Oncology AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-33.40	-38.97	-72.70	-105.95	-277.83

Competitive Comparison of Scandion Oncology AS's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Scandion Oncology AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scandion Oncology AS's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology AS's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Scandion Oncology AS's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Scandion Oncology AS ROE % Adjusted to Book Value Calculation

Scandion Oncology AS's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-190.18%	/	1.38
	=	-137.81%

Scandion Oncology AS's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-383.41%	/	1.38
	=	-277.83%

Scandion Oncology AS ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology AS Headlines

No Headlines